From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|December 12, 2014
Stephanie Baker Justice Discusses How Pharmacists can Learn from their Mistakes
Stephanie Baker Justice, PharmD, BCPS, a pharmacy specialist in the emergency department at Charleston Area Medical Center, discusses how pharmacists can learn from their own errors.
Advertisement
Stephanie Baker Justice, PharmD, BCPS, a pharmacy specialist in the emergency department at Charleston Area Medical Center, discusses how pharmacists can learn from their own errors.
This interview was recorded at the ASHP 2014 Midyear Clinical Meeting in Anaheim, California.
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Glucose Monitoring: Timing Makes Every Reading Count
3
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5